Search our Database of Scientific Publications and Authors

I’m looking for a
    Effect of HPV assay choice on perceived prevalence in a population-based sample.
    Diagn Mol Pathol 2013 Jun;22(2):85-90
    Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, UK.
    Human papillomavirus (HPV) immunization programs clearly have considerable potential to reduce HPV-associated disease; they are also resource-intense; so, it is essential that their effectiveness is determined accurately and in a timely way. Measuring circulating HPV types in a population can provide an early measure of vaccine impact. We assessed the impact of HPV assay on the observed population prevalence of HPV in women who provided samples as part of a National HPV Immunisation Surveillance Exercise. A total of 1145 liquid-based cytology samples, 326 self-taken swabs, and 371 urine samples were tested with a line-blot assay (the Digene reverse hybridization HPV genotyping assay) and a luminex-based assay (the Mulitmetrix HPV genotyping assay). Assay agreement was determined for the different sample types. Positivity (according to assay) was compared at different levels ranging from positive for HPV 16 and/or 18 to positive for any one of the 18 HPV types common to both assays. The luminex assay consistently detected a higher prevalence of HPV--up to 10% for HPV types common to both assays. In addition, disagreement for HPV 16 and/or 18 was observed in around 9% of the overall sample, with an associated κ score of 0.74. These data indicate that assay choice has a significant impact on observed prevalence of HPV, including vaccine types. The impact of any change of assay during longitudinal surveillance programs should thus be taken into account to avoid confounding the assessment of any vaccine-induced changes.

    Similar Publications

    Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.
    BMC Infect Dis 2013 Mar 3;13:114. Epub 2013 Mar 3.
    Cancer Epidemiology Research Unit, Cancer Council NSW 153 Dowling Street, Woolloomooloo, Australia.
    Background: The national Human Papillomavirus (HPV) Immunisation Programme in New Zealand was introduced in 2008, and involves routine vaccination of girls 12-13 years with a catch-up for females aged up to 19 years. The aims of this study were to measure the pre-vaccination prevalence of oncogenic HPV infection in women aged 20-69 years who were participating in the New Zealand National Cervical Screening Programme (NZ-NCSP) and who were: (1) referred with high grade cytology with a subsequent histologically-confirmed high grade cervical intraepithelial neoplasia (CIN2/3) or adenocarcinoma in situ (AIS); or (2) were in the wider group of women who had a cytological prediction of high grade squamous disease or glandular abnormality (ASC-H/ HSIL+/AGC/AIS).

    Methods: Women aged 20-69 years appearing on the NZ-NCSP register between August 2009-February 2011 with a cytology record of ASC-H/HSIL+/AGC/AIS were invited to participate in the study. Read More
    Prevalence of high-risk human papillomavirus by cobas 4800 HPV test in urban Peru.
    Braz J Infect Dis 2014 Sep-Oct;18(5):469-72. Epub 2014 May 15.
    Precisa Laboratorios Arias Stella, Lima, Peru.
    Background: Molecular tests allow the detection of high-risk human papillomavirus in cervical samples, playing an important role in the prevention of cervical cancer.

    Objectives: We performed a study to determine the prevalence of HPV 16, HPV 18 and other high-risk human papillomavirus (pool 12 genotypes) in Peruvian females from diverse urban areas using the cobas 4800 HPV test.

    Methods: Routine cervical samples collected in our laboratory were analyzed by cobas 4800 HPV test. Read More
    There is a high prevalence of human papillomavirus infection in American Indian women of the Northern Plains.
    Gynecol Oncol 2007 Nov 30;107(2):236-41. Epub 2007 Jul 30.
    Cancer Biology Research Institute, Sanford Research, Sanford School of Medicine, The University of South Dakota, Sioux Falls, SD, USA.
    Objectives: Cervical cancer is the leading gynecological malignancy worldwide, and the incidence of this disease is very high in American Indian women. Infection with the human papillomavirus (HPV) is responsible for more than 95% of cervical squamous carcinomas. Therefore, the main objective of this study was to analyze oncogenic HPV infections in American Indian women residing in the Northern Plains. Read More
    Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica.
    J Clin Microbiol 2007 May 7;45(5):1447-54. Epub 2007 Mar 7.
    Division of Cancer Epidemiology and Genetics, Hormonal and Reproductive Epidemiology Branch, National Cancer Institute, 6120 Executive Boulevard, Suite 550, Rockville, MD 20852, USA.
    The objective of this analysis was to compare the performance characteristics of two human papillomavirus (HPV) DNA detections assays, the Hybrid Capture 2 assay (HC2) and the SPF(10) assay, for the detection of carcinogenic HPV. Data are from the enrollment visits of women who participated in the randomized, double-blind, placebo-controlled phase III HPV16/18 Vaccine Trial in Guanacaste, Costa Rica. We compared the results of HC2 and SPF(10) testing of cervical specimens. Read More